MNVA
Minerva discusses roluperidone, targeting negative schizophrenia symptoms
Minerva Neurosciences hosted an investor call to discuss the roluperidone program and its potential to treat negative symptoms within schizophrenia. The event featured guest speakers and an update on clinical research.